The National Prescribing Centre has published MeReC Extra 42 (PDF) which contains information about the risks and benefits of treating adults and children with oseltamivir for the treatment of influenza.
This MeReC Extra directs readers to the online patient decision aids made available earlier this year. Additional information is provided from recent trial work that aimed to assess the benefits of treatment in adults and in children.
Action: Clinicians who issue treatment for patients with symptoms of influenza will find this information useful and informative.
|« November CKS Update||Swine flu ADR reports for Sweden »|